PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: NeonDrum Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ELC Group Appoints Former TOPRA President - World-renowned physician Dr. Paolo Biffignandi joins ELC GROUP’s Advisory Board - ELC-Group.com
ELC Group Appoints Former TOPRA President

 

NewswireToday - /newswire/ - Prague, Czech Republic, 2011/05/11 - World-renowned physician Dr. Paolo Biffignandi joins ELC GROUP’s Advisory Board - ELC-Group.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today announced that former President of The Organisation for Professionals in Regulatory Affairs (TOPRA), Dr. Paolo Biffignandi MD, PhD, QPPV, FTOPRA has joined the ELC GROUP Advisory Board.

Dr.Biffignandi is a world-renowned physician, with PhDs in endocrinology and pharmacology. He is a Fellow of TOPRA, as well as an Overseas Fellow of the Royal Society of Medicine (UK).

Dr.Biffignandi brings over 30 years’ experience in Regulatory Affairs and pharmacovigilance to the company's Advisory Board.

Speaking about the appointment ELC GROUP CEO Marco Rubinstein said: “We are honoured to have Dr Biffignandi join us and his exceptional experience and success throughout his career brings a unique perspective to our advisory board.”
ELC’s Business Development Manager Akhil Jain said: "We are pleased to welcome Paolo to ELC's Advisory Board and look forward to his industry insight and contributions to ELC's strategic plans. ELC has had the privilege to work with Dr.Biffignandi. His experience in the Regulatory Affairs space is immeasurable and his industry contributions are well noted. He is a very experienced addition to our team."

Commenting on his appointment Dr Biffignandi said: “ELC GROUP is the industry expert, and I'm pleased to accept this opportunity to join its Advisory Board and to contribute to its continued strategic success. I look forward to contributing to the company's vision and sharing my experience in Regulatory Affairs."

Press contacts
Akhil Jain, ELC Group - P: +420 22 491 00 00
Miranda Rock, EvokedSet PR - P: +44 (0)7957 391 498

About ELC Group
ELC GROUP (elc-group.com) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries as well as REACH services to the Chemical industry. It helps companies that lack the resource (skills and knowledge) to cost effectively deliver regulatory affairs.

ELC Group provides full-service, multi-lingual consulting and cost-effective solutions to regulatory approvals using experts with in-depth knowledge and experience throughout the world. The team ranges from former FDA investigators to individuals with over 30 years of industry experience with broad capabilities. This includes integrated advanced technologies, regulatory affairs consulting and commercialisation services.

Distributed by NeonDrum.com news distribution service on behalf of EvokedSet.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NeonDrum Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


ELC Group Appoints Former TOPRA President

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Liz Hartney - NeonDrum.com 
+44 7510 518732 news[.]neondrum.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NeonDrum Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NeonDrum Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)